Bioconjugation methods for promoting wound healing are disclosed. In particular, the invention relates to the in situ application of non-photochemical crosslinking techniques such as copper-free click chemistry using strain-promoted azide-alkyne cycloaddition (SPAAC) or multi-functional succinimidyl esters as a therapeutic delivery modality for biomolecules and stem cells to enhance wound healing.

Disclosed are a composition for preventing or treating diabetes, disbesity or diabetic complications, containing an oxyntomodulin analog as an active ingredient and a method for treating diabetes, diabesity or diabetic complications, including administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog shows a greater activity to activate a GLP-1 receptor and a glucagon receptor, than native oxyntomodulin. The oxyntomodulin analog induces an expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in a body weight and appetite to improve insulin sensitivity and is useful in maintaining normal blood glucose levels.

Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.

Tri-component multi-functional boronated complexes (B-complexes), featuring reversible covalent bonds, are described, which incorporate a drug; a water-soluble moiety (e.g. polyethylene glycol (PEG) chains, cyclodextrins); and a targeting unit. A B-complex core was assembled in one step, and proved to be stable in different biocompatible conditions, such as human plasma, though reversible for example in the presence of glutathione (GSH). This platform enabled the modular construction of the multifunctional conjugates exhibiting high selectivity towards, for example, folate-receptor-positive MDA-MB-231 cancer cells, having an IC.sub.50 in the low nanomolar range.

A polyacrylonitrile (PANi) based pharmaceutical composition providing a porous implant for use in treating spinal cord trauma and/or spinal cord injury. Particularly a pharmaceutical composition including polyacrylonitrile (PANi) and/or elastin (E) and/or collagen (C) to form a PANi-E and/or PANi-C and/or a PANi-EC polymer network. Particularly, a pharmaceutical composition including polyacrylonitrile (PANi), elastin (E), and collagen (C) together forming a polyacrylonitrile (PANi), elastin (E), collagen (C) polymer network (PANi-E-C), wherein the polyacrylonitrile (PANi) may be crosslinked to form a crosslinked interpenetrating polyacrylonitrile (PANi), elastin (E) and collagen (C) polymer network (xpi-PANi-E-C), and wherein secondary protein structures of elastin (E) and collagen (C) reorientate. The disclosure extends to use of the pharmaceutical composition in the treatment of spinal cord trauma and/or spinal cord injury.

The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80% identical to one of SEQ ID NOS:1-7, 13-15, 49-50, or 66-70, or a fragment thereof; wherein the peptide is less than 300 amino acids in length.

The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.

Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and/or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.

Provided are biomaterials and methods useful for promoting large blood vessel growth in a subject. An example biomaterial includes a crosslinked hydrogel and a peptide chemically attached to the hydrogel wherein the peptide comprises an extracellular epitope of a cadherin protein. An example method includes administering to an area of the subject a therapeutically effective amount of the biomaterial, wherein the biomaterial provides artery growth, arteriole growth, a combination thereof in the area of administration.

The present disclosure relates to compositions, such as siRNA molecules and FN3 domains conjugated to the same, in combination with enzyme replacement therapies, as well as methods of making and using the same.